Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Fullerton Fund Management Co Ltd.

Fullerton Fund Management Co Ltd. trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 23.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 41,887 shares of the medical research company’s stock after selling 12,882 shares during the quarter. Thermo Fisher Scientific accounts for about 1.3% of Fullerton Fund Management Co Ltd.’s portfolio, making the stock its 21st biggest holding. Fullerton Fund Management Co Ltd.’s holdings in Thermo Fisher Scientific were worth $22,233,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of Thermo Fisher Scientific by 0.6% during the third quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock worth $16,582,503,000 after purchasing an additional 180,618 shares during the period. Morgan Stanley boosted its holdings in shares of Thermo Fisher Scientific by 0.4% in the third quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock worth $6,285,838,000 after buying an additional 50,736 shares during the period. Capital Research Global Investors raised its holdings in shares of Thermo Fisher Scientific by 6.9% during the fourth quarter. Capital Research Global Investors now owns 7,989,614 shares of the medical research company’s stock valued at $4,240,824,000 after acquiring an additional 517,137 shares during the period. Norges Bank purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $2,909,524,000. Finally, Northern Trust Corp grew its position in Thermo Fisher Scientific by 2.6% during the 3rd quarter. Northern Trust Corp now owns 3,929,225 shares of the medical research company’s stock worth $1,988,856,000 after purchasing an additional 99,377 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO traded down $3.06 during trading on Thursday, reaching $572.63. The company had a trading volume of 1,192,292 shares, compared to its average volume of 1,488,205. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The business’s 50 day moving average price is $575.26 and its 200-day moving average price is $557.18. The stock has a market cap of $218.58 billion, a PE ratio of 36.58, a PEG ratio of 2.71 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last announced its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. Analysts expect that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be paid a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date is Friday, June 14th. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Analyst Ratings Changes

Several brokerages have recently commented on TMO. JPMorgan Chase & Co. raised their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Jefferies Financial Group reissued a “buy” rating and issued a $650.00 price target (up from $600.00) on shares of Thermo Fisher Scientific in a research report on Monday, June 3rd. The Goldman Sachs Group upped their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Evercore ISI upped their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Finally, Barclays upped their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research note on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $607.94.

Check Out Our Latest Stock Report on TMO

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at approximately $70,873,516.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the sale, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total value of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares of the company’s stock, valued at $7,430,359.02. The disclosure for this sale can be found here. Insiders have sold a total of 22,000 shares of company stock worth $12,532,780 over the last three months. Corporate insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Articles

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.